• KOL
    • Endothelin Receptor Antagonists
    • Kunshen Liu
    • Kunshen Liu: Influence Statistics

      Kunshen Liu

      Kunshen Liu

      The First Hospital of Hebei Medical University, Shijiazhuang, China. | The First Cardiology Division The First Hospital of Hebei Medical University Shijiazhuang China. | From ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Kunshen Liu:Expert Impact

      Concepts for whichKunshen Liuhas direct influence:Endothelin receptor antagonists,Pulmonary arterial hypertension,Diuretic resistance,Cardiac surgery,Receptor antagonists,Endothelin receptor,Renal artery stenosis,Pulmonary arterial.

      Kunshen Liu:KOL impact

      Concepts related to the work of other authors for whichfor which Kunshen Liu has influence:Pulmonary arterial hypertension,Endothelin receptor antagonists,Rat plasma,Generic drugs,Pharmacokinetic study,Diuretic resistance,Simultaneous determination.

      KOL Resume for Kunshen Liu

      Year
      2021

      The First Hospital of Hebei Medical University, Shijiazhuang, China.

      2020

      The First Cardiology Division The First Hospital of Hebei Medical University Shijiazhuang China.

      2015

      From the Heart Center, The First Hospital of Hebei Medical University, Shijiazhuang, China.H. Meng, MD; G. Liu, MD, J. Zhai, MD; Y. Zhen, MD; Q. Zhao, MD; M. Zheng, MD; G. Ma, MD; L. Wang, MD; L. Tian, MD; L. Ji, MD; L. Duan, MD; L. Li, MD; K. Liu, MD; C. Liu, MD, The First Hospital of Hebei Medical University.

      Heart Center, The First Hospital of Hebei Medical University, 89 Donggang Road, Shijiazhuang, Hebei Province 050031, China.

      2014

      Heart Center, The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China.

      Department of Cardiology, The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China

      2013

      Heart Center, The First Hospital of Hebei Medical University, Hebei Province, China

      2010

      Heart Center, The First Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, People's Republic of China

      2009

      First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

      2008

      Cardiology Department, Hebei Medical University

      2007

      Cardiology Department, First Hospital of Hebei Medical University, Hebei Medical University, Hebei, China

      2006

      From the Cardiology Department, Hebei Medical University, Shijiazhuang, Hebei.

      The First Hospital of Hebei Medical University, Hebei Medical University, 89 Donggang Road, Shijiazhuang, Hebei Province 050031, People's Republic of China

      2005

      Cardiology Department, The First Affiliated Hospital of Hebei Medical University

      Sample of concepts for which Kunshen Liu is among the top experts in the world.
      Concept World rank
      potent diuretic effects #2

      Prominent publications by Kunshen Liu

      KOL-Index: 18386

      BACKGROUND: Pulmonary arterial hypertension is a devastating disease, which leads to right heart failure and premature death. Recent evidence suggests that endothelin receptor antagonists may be promising drugs in the treatment of pulmonary arterial hypertension.

      OBJECTIVES: To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension.

      SEARCH STRATEGY: We searched CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE, EMBASE, and the ...

      Known for Endothelin Receptor Antagonists | Pulmonary Arterial Hypertension | 95 Confidence Interval | Nyha Functional Class | Patients Trials
      KOL-Index: 16861

      BACKGROUND: Pulmonary arterial hypertension is a devastating disease, which leads to right heart failure and premature death. Recent evidence suggests that endothelin receptor antagonists may be promising drugs in the treatment of pulmonary arterial hypertension.

      OBJECTIVES: To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension.

      SEARCH METHODS: We searched CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE, EMBASE, and the reference ...

      Known for Endothelin Receptor Antagonists | Pulmonary Arterial Hypertension | Functional Class | Irreversible Liver Failure | Premature Death
      KOL-Index: 9120

      In heart failure, the renal responsiveness to exogenous and endogenous atrial natriuretic peptide (ANP) is blunted. The mechanisms of renal hyporesponsiveness to ANP are complex, but one potential mechanism is decreased expression of natriuretic peptide receptor-A (NPR-A) in inner medullary collecting duct (IMCD) cells. Newly emerging evidence shows that glucocorticoids could produce potent diuresis and natriuresis in patients with heart failure, but the precise mechanism is unclear. In ...

      Known for Heart Failure | Natriuretic Peptide | Renal Responsiveness | Wistar Receptors | Dex Anp
      KOL-Index: 8106

      Animal studies showed glucocorticoids could specifically dilate renal vasculature, regulate synthesis and release of atrial natriuretic peptide (ANP), upregulate ANP receptors on vascular endothelial cells, and thus have potent potentiating diuresis and natriuresis effects in animal studies; however, their diuretic efficacy in humans is yet to be known. Therefore, we designed this randomized, double- blind, placebo-controlled, clinical study to determine the diuretic efficacy of ...

      Known for Heart Failure | Serum Creatinine | Diuretic Effects | Animal Studies | Urine Volume
      KOL-Index: 7973

      AIMS: cardiopulmonary bypass and cardiac surgery are associated with a significant systemic inflammatory response that has been suggested playing a causative role in the development of perioperative atrial fibrillation (POAF). The goal of this meta-analysis was to determine the efficacy of glucocorticoid prophylaxis in preventing POAF, or length of intensive care unite (ICU) or hospital stay.

      METHODS: A systematic electronic database literature search of Cochrane controlled trials ...

      Known for Cardiac Surgery | Atrial Fibrillation | Poaf Length | Icu Stay | Randomized Controlled
      KOL-Index: 7680

      BACKGROUND: Chronic drug interactions that exist between symptomatic congestive heart failure (CHF) therapy and pharmacologic agents used for hyperuricemia and gout are a challenging problem in clinical practice. Recent observational studies showed that prednisone can induce a potent diuresis and lower serum uric acid concentration (SUA) in CHF. We therefore designed a randomized study to compare the effect of prednisone with allopurinol on SUA in symptomatic CHF patients with ...

      Known for Uric Acid Lowering | Heart Failure | Clinical Status | Potent Diuresis | Serum Creatinine
      KOL-Index: 7571

      BACKGROUND: Refractory congestive heart failure (CHF) with diuretic resistance is life-threatening and predicts a short life expectancy. Glucocorticoids have been proven to have potent diuretic effects in animal studies; however, their efficacy in CHF patients with diuretic resistance is not known.

      METHODS: Thirteen CHF patients with significant volume overload and diuretic resistance who failed to respond to a conventional sequential nephron blockade therapeutic strategy; that is, the ...

      Known for Diuretic Resistance | Renal Function | Chf Patients | Heart Failure | Volume Overload
      KOL-Index: 6812

      Atrial natriuretic peptide (ANP) provides a potent defense mechanism against volume overload in mammals. Its primary receptor, natriuretic peptide receptor-A (NPR-A), is localized mostly in the kidney, but also is found in hypothalamic areas involved in body fluid volume regulation. Acute glucocorticoid administration produces potent diuresis and natriuresis, possibly by acting in the renal natriuretic peptide system. However, chronic glucocorticoid administration attenuates renal water ...

      Known for Natriuretic Peptide | Wistar Receptors | Potent Diuresis | Renal Water | Volume Depletion
      KOL-Index: 5883

      Diuretic resistance in heart failure is defined as a state in which diuretic response is diminished or lost before the therapeutic goal of relief from congestion has been reached. Diuretic resistance is very common and is associated with poor outcomes. Over the past decade, several new drugs and devices targeting decongestion and improvement in renal function in patients with heart failure have failed to show benefit in randomized clinical trials. Glucocorticoids had been used to manage ...

      Known for Diuretic Resistance | Heart Failure | Glucocorticoid Therapy | Renal Function
      KOL-Index: 4699

      Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited heart muscle disease associated with increased risks of sudden death, particularly in young, otherwise healthy, patients. The pathologic features are progressive myocardial atrophy and fibrofatty replacement. Plakophilin-2 (PKP2) is reported as the most common ARVD/C-causing gene in Western countries. In this study we aimed to determine the prevalence of PKP2 mutations in Chinese patients with ARVD/C and ...

      Known for Pkp2 Mutations | Patients Arvd | Arrhythmogenic Ventricular | Sudden Death | Fibrofatty Replacement
      KOL-Index: 4433

      OBJECTIVE: To determine the safety and efficacy of prednisone in patients with symptomatic heart failure (HF) and hyperuricemia.

      METHODS: Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl).

      RESULTS: Prednisone significantly reduced serum uric acid by 2.99 mg/dl (p < 0.01) and serum creatinine by 0.17 mg/dl (p < 0.01). These favorable effects were associated with a remarkable increase in urine output, ...

      Known for Uric Acid | Heart Failure | Serum Creatinine | Urine Output | Conclusion Prednisone
      KOL-Index: 4119

      The aim of the present study was to determine if prednisone, a glucocorticoid, added to conventional treatment for patients with decompensated congestive heart failure (DCHF) refractory to the conventional care, results in significant relief of congestive symptoms and improvement of clinical status. Diuretic-based strategies, as the mainstay in DCHF management, are not always effective in eliciting diuresis. However, the addition of prednisone to standard care may induce potent diuresis ...

      Known for Heart Failure | Potent Diuresis | Renal Function | Clinical Status | Daily Urine Volume
      KOL-Index: 3943

      BACKGROUND: Recent evidence indicates that prednisone can potentiate renal responsiveness to diuretics in heart failure (HF). However, the optimal dose of prednisone is not known.

      METHOD: Thirty-eight patients with symptomatic HF were randomized to receive standard HF care alone (n = 10) or with low-dose (15 mg/d, n = 8), medium-dose (30 mg/d, n = 10), or high-dose prednisone (60 mg/d, n = 10), for 10 days. During this time, we recorded the 24-hour urinary output and the 24-hour urinary ...

      Known for Heart Failure | Dose Prednisone | Urine Output | Standard Hf | Potent Diuresis
      KOL-Index: 3927

      INTRODUCTION: Newly emerging evidence showed that glucocorticoids could potentiate natriuretic peptides' action by increasing the density of natriuretic peptide receptor A, leading to a potent diuresis and a renal function improvement in patients with acute decompensated heart failure (ADHF). Therefore, glucocorticoid therapy may be used in patients with ADHF.

      METHODS: One hundred two patients with ADHF were randomized to receive glucocorticoids or standard treatment. Change from ...

      Known for Heart Failure | Glucocorticoid Therapy | Serum Creatinine | Potent Diuresis | Acute Decompensated

      Key People For Endothelin Receptor Antagonists

      Top KOLs in the world
      #1
      Masashi M Yanagisawa
      orexin neurons endothelin receptor knockout mice
      #2
      Tomoh Masaki
      endothelial cells endothelin receptors oxidized ldl
      #3
      Sadao K Kimura
      tumor cells spinal cord thermal hyperalgesia
      #4
      Katsutoshi Katsutoshi
      endothelin receptor orexin neurons gene expression
      #5
      Gérald Simonneau
      pulmonary hypertension lung transplantation patients pah
      #6
      Lewis J Rubin
      pulmonary arterial hypertension inhaled treprostinil combination therapy
      Select a search phrase   endothelin receptor antagonists

      The First Hospital of Hebei Medical University, Shijiazhuang, China. | The First Cardiology Division The First Hospital of Hebei Medical University Shijiazhuang China. | From the Heart Center, The First Hospital of Hebei Medical University, Shijiazhu

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.